Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L)-Reference-Cited by-同舟云学术

Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L)

Published:2021-05 Issue: Volume:155 Page:68-77
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Garcia Campelo Maria Rosario,Lin Huamao M.,Zhu Yanyan,Pérol Maurice^ORCID,Jahanzeb Mohammad,Popat Sanjay,Zhang Pingkuan,Camidge D. Ross

Funder

Ariad Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. American Cancer Society, What Is Non-small Cell Lung Cancer?,2021

2. Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective;Jiang;Acta Pharm. Sin. B,2018

3. Second- and third-generation ALK inhibitors for non-small cell lung cancer;Wu;J. Hematol. Oncol.,2016

4. XALKORI [prescribing information],2021

5. ALCENSA [prescribing information],2021

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epinephrine, Pregabalin, and Crizotinib as Three Medicines with Polish Implications over Three Last Centuries and in View of Three Different Drug Discovery Approaches;Biomedicines;2024-09-04

2. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis;BMC Cancer;2024-02-08

3. Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non–Small Cell Lung Cancer in ALTA-1L Trial;Value in Health;2024-02

4. A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer;Journal of Thoracic Disease;2023-04

5. Keratin19 promotes pancreatic cancer progression and poor prognosis via activating the Hedgehog pathway;International Journal of Oncology;2023-02-21